Mode
Text Size
Log in / Sign up

Network meta-analysis of sedation strategies in therapeutic gastrointestinal endoscopy shows ketamine-propofol reduces hypoxia and bradycardia versus propofol-opioidBetter Sedation Choices Could Reduce Side Effects During Stomach Tests

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider ketamine-propofol for therapeutic GI endoscopy; moderate certainty for reduced hypoxia and bradycardia versus propofol-opioid.

This systematic review conducted as a network meta-analysis examined pharmacological sedation strategies for patients undergoing therapeutic gastrointestinal endoscopy. The analysis included data from 7,071 patients and compared various agents including propofol, opioid, ketamine, lidocaine, and midazolam against a propofol-opioid comparator. Secondary outcomes assessed included procedural interference events, hypoxia, hypotension, bradycardia, recovery time, induction time, satisfaction, and postoperative nausea and vomiting.

The primary synthesized findings demonstrated that ketamine-propofol regimens showed consistent advantages over propofol-opioid regarding specific adverse events. Specifically, the use of ketamine-propofol was associated with a reduction in hypoxia, with a relative risk of 0.12 (95% CI 0.03 to 0.59, P = 0.009). Similarly, bradycardia rates were reduced with a relative risk of 0.11 (95% CI 0.01 to 0.86, P = 0.035). The analysis also found a reduction in hypotension with a relative risk of 0.28 (95% CI 0.09 to 0.83, P = 0.021).

The authors assigned moderate certainty to the findings for hypoxia and bradycardia, while assigning low certainty to the finding for hypotension. Adverse events, serious adverse events, discontinuations, and tolerability were not reported in the source data. No specific limitations were explicitly noted by the authors in the provided text. Consequently, these findings support individualized regimen selection based on patient and procedural needs rather than establishing a single universal standard.

Finding the right sedation balance

Imagine lying on a table, ready for a procedure. You want to sleep through it comfortably. But you also want to wake up feeling okay.

Doctors use medicine to help you relax during these tests. Sometimes, the drugs cause unwanted side effects.

The usual choice for sedation

For years, doctors used a mix of propofol and opioids. This combination is the standard choice for most patients.

It works well for many people. But here’s the twist. It is not perfect for everyone.

Some patients experience drops in blood pressure or slower breathing. These risks are higher during longer procedures.

A surprising shift in data

Researchers looked at many different drug combinations. They wanted to find safer options for everyone.

They reviewed sixty studies involving over seven thousand patients. This is one of the largest reviews of its kind.

How the drugs work together

Think of sedation like a dimmer switch on a light. You need enough light to see, but not too much glare.

Some drugs turn the switch too far down. This can make breathing difficult or slow the heart.

This study found a mix that keeps the light steady. It offers a safer path for sensitive patients.

The numbers behind the news

The team compared thirty-two different drug regimens. They measured safety and how well the procedure went.

No drug beat the standard on stopping procedure interruptions. But the ketamine-propofol mix was safer for breathing.

It lowered the risk of low oxygen levels significantly. It also reduced drops in blood pressure and heart rate.

This doesn’t mean this treatment is available yet.

What experts say about this

Experts suggest choosing drugs based on the patient. One size does not fit all in medicine.

Some people need the standard mix. Others need the new option.

The goal is to match the drug to the person. This helps reduce risks during the procedure.

You cannot ask for this specific mix at your appointment. It is still part of ongoing research.

However, knowing this helps you ask better questions. Talk to your doctor about your specific risks.

Important limits to keep in mind

The study had some weaknesses. It looked at many different drugs at once.

Some comparisons had less evidence than others. We need more data to be sure.

The road ahead for patients

More trials are needed to confirm these results. Doctors will watch how patients respond over time.

Approval takes time to ensure safety for everyone. This is a step toward better care.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundTherapeutic gastrointestinal endoscopy, including endoscopic retrograde cholangiopancreatography and endoscopic submucosal dissection, requires effective sedation strategies to ensure procedural success and patient safety. However, optimal pharmacological regimens remain unclear, particularly for prolonged procedures.MethodsWe searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) for randomised controlled trials comparing pharmacological sedation strategies in patients undergoing therapeutic gastrointestinal endoscopy. Outcomes included procedural interference events, hypoxia, hypotension, bradycardia, recovery time, induction time, satisfaction, and postoperative nausea and vomiting. Risk of bias was assessed using the Cochrane RoB 2.0 tool, and certainty of evidence was rated using GRADE framework. A frequentist random-effects network meta-analysis was conducted, along with cluster ranking of co-primary outcomes to evaluate benefit-risk trade-offs.ResultsSixty randomised controlled trials involving 7,071 patients and 32 pharmacological regimens were included. Compared with propofol-opioid, which remained the reference standard, no regimen significantly reduced procedural interference events. Ketamine-propofol demonstrated consistent advantages across hypoxia (relative risk [RR] 0.12, 95% confidence interval [CI] 0.03 to 0.59, P = 0.009; moderate certainty), hypotension (RR 0.28, 95% CI 0.09 to 0.83, P = 0.021; low certainty), and bradycardia (RR 0.11, 95% CI 0.01 to 0.86, P = 0.035; moderate certainty). Cluster rank analyses identified ketamine-propofol and lidocaine-midazolam-propofol as the highest-ranking regimens in both efficacy and safety domains. Meta-regression revealed no significant effect modifiers.ConclusionWhile propofol-opioid remains the standard reference, alternative sedation strategies such as ketamine-propofol and lidocaine-midazolam-propofol offer favourable profiles for therapeutic gastrointestinal endoscopy. These findings support individualised regimen selection based on patient and procedural needs.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251018215.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.